

VERNEREY Déwi
3 le coteau
25115 POUILLEY-LES-VIGNES
dvernerey@chu-besancon.fr
French citizenship
Driving license



Research Engineer in Epidemiology & Biostatistics (Ph.D. / + 14 years' experience)

➤ WORK EXPERIENCE

- Since 2013 **Research Engineer in Epidemiology & Biostatistics** (permanent contract **CHRU: "Ingenieur Hospitalier Principal"**) in the Methodology and quality of life in Oncology Unit (UMQVC) **at the University hospital of Besancon.**
- Teacher (vacation university)** in statistics, data analysis and methodology in master's degree and in medical school.
- 2010 – 2013 **Research Engineer in Epidemiology & Biostatistics** (permanent contract **INSERM**) at PARCC (Paris Cardiovascular Research Center) located in Georges Pompidou European hospital.
- 2008 – 2010 **Biostatistician** (permanent contract) at «**Genetic diseases Institute**» in Necker Hospital.
- 2006 – 2008 **Research Engineer in Statistics** (fixed-term contract) at **INSERM U535 Unit** (Epidemiologic Genetics and Human Populations Structure - Paul Brousse Hospital - Villejuif).
- 2005 **Biostatistician** (fixed-term contract) at **Sanofi Aventis R&D Center** (Chilly Mazarin)
- 2005 **Teacher at Public Health and Epidemiology Summer School** « *Ecole d'été de santé publique et d'épidémiologie* » at Paris XI University (Kremlin Bicêtre Hospital)
- 2004 – 2005 **Biostatistician** (fixed-term contract) in « **Institut Gustave Roussy** » (IGR-Villejuif) Biostatistics and Epidemiology department.

➤ EDUCATION

- 2013 – 2016 **PhD in epidemiology and statistics**
Burgundy and Franche-Comté University.
- 2002 – 2003 **Master's degree in Mathematical Engineering** - major: Engineering Statistics – graduated cum laude
Joseph Fourier University, Grenoble 38.
- 1999 – 2002 **Bachelor and Master's degree in Mathematics** - graduated cum laude
- Two-Year University degree in Mathematics and Informatics Applied to Science**-graduated cum laude
« UFR Sciences et Techniques » of Franche-Comté, Besançon, 25.
- 1999 **BACCALAUREAT in Science (major mathematic)** followed by a one-year preparatory classes for entrance to "Grandes Ecoles" in the field of science
Victor Hugo High School, Besançon 25.

➤ ADVISORY BOARD

Since 2017 Member of the HaliDx's Digestive Scientific Advisory Board (2017-2019)

Since 2017 Member of the ARCAD Foundation's Scientific Advisory Board (2017-XXXX)

➤ INTERNATIONAL AND NATIONAL RESPONSABILITIES

Since 2017 Member of the ARCAD group

Since 2017 Head of GERCOR statistical team (INCA's labeled data center)

➤ FIELD OF EXPERTISE

Epidemiology, Biostatistics, Clinical trials design and Analysis

Clinical Research

Oncology, Kidney and Heart Transplantation, Cardiovascular diseases, Monogenic genetic diseases (rare) & multifactorial (frequent), Pathology, Immunology, transfusion

➤ MAJOR 15 PUBLICATIONS

1. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J, Souglakos L, Shi Q, Kerr R, Labianca R, Meyerhardt J, **Vernerey D**, Yamanaka T, Boukovinas L., Meyers J, Renfro L, Niedzwiecki D, Torri V, Sargent D, Andre T, Iveson T
Duration (3 versus 6 months) of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer
New England Journal of Medicine (2018)
Impact factor: 72.4
2. Thierry A, **Vernerey D**, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France phase III trial
Journal of Clinical Oncology (2018)
Impact factor: 24.0
3. Auclin E, Zaanan A, **Vernerey D**, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
Annals of Oncology (2017)
Impact factor: 11.9
4. Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart A-C, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, **Vernerey D**
Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma
Journal of the National Cancer Institute (2017)
Impact factor: 12.8

5. **Vernerey D**, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).
British Journal of Cancer (2016)
 Impact factor: 5.6

6. Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
International Journal of Cancer (2016)
 Impact factor: 5.5

7. André T, de Gramont A, **Vernerey D**, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriver A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Journal of Clinical Oncology. (2015)
 Impact factor: 24.0

8. Tournigand C, Chibaudel B, Samson B, Scheithauer W, **Vernerey D**, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
The Lancet Oncology. (2015)
 Impact factor: 33.9

9. Aubert O*, Kamar N*, **Vernerey D***, Viglietti D, Martinez F, Duong-Van-Huyen J-P, Eladari D, Empana J-P, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A
Long-term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.
British Medical Journal. (2015)
*Co first authorship
 Impact factor: 20.0

10. Loupy A*, **Vernerey D***, Viglietti D*, Aubert O, Duong Van Huyen J-P, Empana J-P, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C
Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.
Circulation Research (2015)
*Co first authorship
 Impact factor: 11.6

11. Loupy A*, **Vernerey D***, Tinel C, Aubert O, Duong van Huyen J-P, Rabant M, Verine J, Nochy D, Empana J-P, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
Journal of the American Society of Nephrology (2015)
*Co first authorship
 Impact factor: 10

12. Jary M*, **Vernerey D***, Lecomte T, Dobi E, Ghiringhelli F, Monnier F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C
Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.
Cancer Epidemiology, Biomarkers & Prevention (2015)
*Co first authorship
Impact factor: 5
13. Loupy A, Lefaucheur C, **Vernerey D**, Prugger C, Duong van Huyen J-P, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana J-P, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X
Complement-binding anti-HLA antibodies and kidney-allograft survival.
New England Journal of Medicine (2013)
Impact factor: 52
14. Lefaucheur C, Loupy A, **Vernerey D**, Duong-Van-Huyen J-P, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana J-P, Hill GS, Glotz D, Legendre C, Jouven X
Antibody-mediated vascular rejection of kidney allografts: a population-based study.
The Lancet (2013)
Impact factor: 38
15. Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, Périer M-C, Marijon E, **Vernerey D**, Empana J-P, Jouven X
Main air pollutants and myocardial infarction: a systematic review and meta-analysis.
JAMA (2012)
Impact factor: 30

➤ MAJOR COMMUNICATIONS

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

- Oral Communication at the Annual meeting of the French Pancreatic Club in 2014, Paris, France.
- Oral Communication at the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain.
- Oral Communication at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in 2015, San Francisco, United States of America
- Oral Communication at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in 2014, Barcelona, Spain.
- Poster discussion at the American Society of Clinical Oncology Annual meeting in 2014, Chicago, United States of America.
- Selection for poster of distinction at the American Pancreatic Association in 2015, San Diego, United States of America.

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

- Best Abstract in Clinical Science at the Annual meeting of the French Pancreatic Club in 2014, Paris, France
- Best Abstract in Clinical Science at the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

- Best Abstract in Colorectal Cancer at the JFHOD annual congress in 2016, Paris, France